News
LABT ▲ +12.6% - Lakewood-Amedex Biotherapeutics, Inc.
LABT ▲ +12.6% - Lakewood-Amedex Biotherapeutics, Inc.
$LABT - Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Lakewood-Amedex Biotherapeutics shares rose 12.6% following a CEO letter to shareholders that highlighted transformational progress and the outlook for the company's Nu-3 program. The positive messaging about advancement in the pipeline candidate appears to have boosted investor confidence in the biotech firm's direction.
21-SEP-2026 08:02 AM ET
Share this post
More filings for $LABT
LABT ▲ +5.3% - Lakewood-Amedex Biotherapeutics, Inc.Sep 18, 2026LABT ▲ +1.1% - Lakewood-Amedex Biotherapeutics, Inc.Sep 8, 2026LABT ▲ +47.8% - Lakewood-Amedex Biotherapeutics, Inc.Aug 31, 2026LABT ▲ +47.8% - Lakewood-Amedex Biotherapeutics, Inc.Aug 31, 2026LABT ▲ +47.8% - Lakewood-Amedex Biotherapeutics, Inc.Aug 31, 2026LABT - Lakewood-Amedex Biotherapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $LABT filing history →💬 Comments
Loading comments…
Leave a comment
